Gilead Sciences (CH:GILD)
NASDAQ:GILD
GILD Stock Chart & Stats
CHF108.14
CHF0.00(0.00%)
Market closed
CHF108.14
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF67.87 - CHF121.37
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
CHF124.97B
Enterprise ValueCHF181.45B
Total Cash (Recent Filing)CHF9.82B
Total Debt (Recent Filing)CHF22.17B
Price to Earnings (P/E)17.2
Beta0.15
Next Earnings
Jul 30, 2026EPS Estimate
-5.2Next Dividend Ex-DateN/A
Dividend Yield2.64%
Share Statistics
EPS (TTM)7.42
Shares Outstanding1,241,569,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)6.75
Price to Sales (P/S)5.19
P/FCF Ratio16.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF126.09Price Target Upside16.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)0.21
Revenue Forecast (FY)CHF24.02B
Bulls Say, Bears Say
Bulls Say
High Margins And Cash GenerationSustained very high gross and operating margins underpin durable free cash flow and internal funding for R&D, launches, share repurchases, and debt flexibility. Strong margin structure supports capital allocation and cushions the business against cyclic revenue swings over the next several quarters.
Leading HIV Franchise And PrEP MomentumA dominant HIV portfolio with significant U.S. share and accelerating PrEP adoption drives recurring, chronic-treatment revenue. This franchise provides predictable, defendable cash flows and pricing power that reduce revenue cyclicality and support long-term organic stability.
Conservative Balance Sheet And Cash Flow ProfileLow leverage and solid free-cash-flow conversion give strategic optionality to pursue acquisitions, fund pipeline investments, and sustain shareholder returns. This balance-sheet strength supports multi-quarter execution on M&A and clinical programs without immediate liquidity strain.
Bears Say
Limited Organic Revenue GrowthHistorical low-single-digit top-line growth constrains intrinsic upside and increases reliance on new launches, label expansions, and acquisitions to drive meaningful revenue gains. Without durable higher organic growth the company must continually execute launches or transactions to expand scale.
Large Transaction Charges And Tax DistortionMassive upfront IPR&D charges and nondeductible transaction costs materially distort reported EPS and create an unusually high effective tax rate. That complicates near-term performance assessment, may impair investor confidence, and will persist in reported metrics across fiscal 2026.
Cell Therapy Near-term Revenue Pressure And CompetitionKite's cell-therapy revenues face in‑class competition and sequential declines, creating execution risk for near-term growth. Combined with reliance on approvals and commercial execution for recent acquisitions, this weakens short-to-medium term revenue contribution from the oncology cell-therapy franchise.
Gilead Sciences News
GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was CHF67.87 and its highest was CHF121.37 in the past 12 months.
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is CHF124.97B.
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Jul 30, 2026 which is in 56 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on May 07, 2026. The company reported CHF1.602 earnings per share for the quarter, beating the consensus estimate of CHF1.506 by CHF0.095.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of CHF0.71 which represents an annual dividend yield of 2.64%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is -5.2.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,241,569,800 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of CHF1.602 in its last earnings report, beating expectations of CHF1.506. Following the earnings report the stock price went down -1.924%.
Which hedge fund is a major shareholder of Gilead Sciences?
Currently, no hedge funds are holding shares in CH:GILD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gilead Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF126.09 (16.60% Upside)
CHF126.09 (16.60% Upside)
Blogger Sentiment
Bullish
CH:GILD Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 79%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.24%
12-Months-Change
Fundamentals
Return on Equity
42.20%
Trailing 12-Months
Asset Growth
-0.28%
Trailing 12-Months
Company Description
Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD Company Deck
GILD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum across core franchises—particularly HIV (including PrEP), oncology (Trodelvy), and the rapid Libdelzi launch—resulting in raised revenue guidance, improved EPS and high margins. At the same time, near-term financials are materially impacted by large upfront acquisition-related IPR&D charges and associated tax consequences, alongside expected seasonal and cell therapy revenue headwinds. Overall the company delivered strong operational execution and a strengthened pipeline, but shareholders face short-term headline earnings pressure from the transactions.View all CH:GILD earnings summariesGILD Revenue Breakdown
70.48% HIV
10.93% Liver Disease
3.09% Veklury
10.99% Oncology
2.71% Other
1.79% Royalty, contract and other revenues
GILD Stock 12 Month Forecast
Average Price Target
CHF126.09
▲(16.60% Upside)
Technical Analysis
Options Prices
Currently, No data available
---